Development of new therapeutic approaches against chronic liver diseases with combination of hepatic progenitor cells and clinical available agents
Project/Area Number |
26461017
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Nara Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
北出 光輝 奈良県立医科大学, 医学部, 学内講師 (40526795)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 肝線維化 / 肝再生 / 肝前駆細胞 / 選択的NOTCH1阻害薬 / アンジオテンシン受容体阻害薬 |
Outline of Final Research Achievements |
During the period of this grant, we revealed many new findings about the usefulness of the combined cocktail therapy with hepatic progenitor cells (HPC) and clinical available agents such as angiotensin II receptor blocker (ARB) in several types of animal models of liver fibrosis development and hepatocarcinogenesis. Even at clinical comparable low doses of these agents, we observed significant inhibitory effects on the liver fibrosis development, hepatocarcinogenesis, and the growth of hepatocellular carcinoma (HCC) with many publications in international journals. Furthermore, we observed that specific NOTCH-1 inhibitor significantly suppressed the liver fibrosis development along with augmentation of hepatic regeneration. It is well known that augmentation of liver regeneration would play a pivotal role for improvement of hepatic reserve. Collectively, our studies with this grant could contribute to the improvement of prognosis in patients with chronic liver diseases.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
-
-
-
[Journal Article] Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.2016
Author(s)
Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H
-
Journal Title
Jounal of Gastroenterology
Volume: 51
Issue: 2
Pages: 162-72
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats2016
Author(s)
Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, Takeda K, Okura Y, Aihara Y, Douhara A, Kawaratani H, Asada K, Yoshiji H
-
Journal Title
J Gastroenterol.
Volume: Mar 29
Issue: 12
Pages: 1141-1149
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Presentation] Impact of the combination of dipeptidyl peptidase IV inhibitor and angiotensin-Ⅱtype 1 receptor blocker on hepatocarcinogenesis in a rat model of nonalcoholic steatohepatitis2016
Author(s)
Okura Y, Namisaki T, Noguchi R, Takeda K, Moriya K, Kitade M, Nishimura N, Sato S, Sawada Y, Kawaratani H, Seki K, Kaji K, Yoshiji H
Organizer
EASL
Place of Presentation
Spain Barcelona
Year and Date
2016-02-23
Related Report
Int'l Joint Research
-
[Presentation] Antifirotic effects of combined treatment with farnesoid X receptor agonist and angiotensin-Ⅱtype1 receptor blocker on hepatic fibrogenesis in the rat model of nonalcoholic steatohepatitis2016
Author(s)
Namisaki T, Okura Y, Sato S, Noguchi R, Moriya K, Kitade M, Takeda K, Nishimura N, Sawada Y, Seki K, Kawaratani H, Kaji K, Yoshiji H
Organizer
EASL
Place of Presentation
Spain Barcelona
Year and Date
2016-02-23
Related Report
Int'l Joint Research
-
-
-